Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $41.92 Analyst target: $60.50 Upside: 44.32%
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
See the full interactive analysis & chart →Informational only — not investment advice.